EGFR and neoplasm: Therefore, despite how EGFR mutations upregulate the constitutive expression of PD-L1 in tumor cells, the concomitant shortage of activated tumor infiltrating lymphocytes in EGFR-mutated NSCLC (291, 292) may weaken the inducible PD-L1 expression.